← All articles

Trump tariff order creates tiered pharmaceutical import rates

An executive order establishes tiered tariff rates on patented drugs: 0% for companies with favorable pricing deals, 15% for EU/Japan/Korea/Switzerland, and up to 100% for others. PhRMA warns the policy could raise medicine costs and reduce domestic investment.

AI-assisted reporting

The essentials

Executive order creates 0-100% pharmaceutical tariffs tied to pricing agreements and trading partners.

An executive order signed in Washington establishes a differentiated tariff structure for patented drugs, ranging from 0% to 100% depending on pricing agreements and country of origin.

Companies with 'most favored nation' pricing deals receive a 0% tariff rate, creating an incentive for domestic price negotiations. The EU, Japan, Korea, and Switzerland face a 15% tariff rate on patented pharmaceuticals, while other trading partners could face rates up to 100%.

The Pharmaceutical Research and Manufacturers of America (PhRMA) has warned that tariffs could increase medicine costs and potentially jeopardize U.S. pharmaceutical investment. The tiered approach reflects a strategy to link trade policy with domestic drug pricing outcomes.

Broaden the view

Other ways to read this story.

Alternative framings generated by SigNews. These are not independent sources or attributed quotations.

Policy Structure

Tariff framework links drug pricing to trade compliance mechanisms

The order establishes three tariff tiers: 0% for most-favored-nation pricing agreements, 15% for specified allied nations, and up to 100% for others. This structure creates direct economic incentives for pharmaceutical companies to adopt lower domestic pricing, effectively using tariff policy as a regulatory tool to influence drug costs without direct price controls.

Industry Response

PhRMA raises concerns about cost increases and investment impacts

The pharmaceutical industry warns of potential medicine cost increases and reduced U.S. investment incentives resulting from tariffs. Industry representatives argue the tiered structure may encourage price negotiations but express concern that higher tariff rates could be passed to consumers and discourage pharmaceutical research and development spending domestically.